SCHEMBL7965088

SCHEMBL7965088

Cc1nc2ccccn2c1-c1ccnc(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 10/20 0.54
CDK4 P11802 5/20 0.54
ALDH1A1 P00352 6/20 0.52
GAA P10253 3/20 0.52
MAPT P10636 3/20 0.52
POLB P06746 1/20 0.52
NCOA1 Q15788 1/20 0.52
NCOA3 Q9Y6Q9 1/20 0.52
CCNE1 P24864 4/20 0.49
KDM4E B2RXH2 5/20 0.48
GLA P06280 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PIK3CA P42336 1/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 1/20 0.46
XIAP P98170 1/20 0.43
BIRC2 Q13490 1/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10252170 0.83 COMT (0.52) CDK2CDK4ALDH1A1GAAMAPT
SCHEMBL947308 0.79 CDK2 (0.55) CDK2CDK4ALDH1A1GAAMAPT
SCHEMBL7974764 0.79 PI4KB (0.38) DYRK1A
SCHEMBL17231254 0.79 CDK2 (0.56) CDK2CDK4ALDH1A1GAAMAPT
SCHEMBL21208130 0.77 CDK2 (0.48) CDK2CDK4ALDH1A1GAAMAPT
SCHEMBL9611707 0.77 ALDH1A1 (0.56) CDK2CDK4ALDH1A1GAAMAPT
SCHEMBL24276363 0.76 PIK3CA (0.49) CDK2CDK4ALDH1A1GAAMAPT
SCHEMBL21217063 0.75 PRKDC (0.52) CDK2CDK4ALDH1A1GAAMAPT
SCHEMBL21208129 0.75 CSNK1E (0.47) CDK2CDK4ALDH1A1GAAMAPT
SCHEMBL14682567 0.74 ALDH1A1 (0.54) CDK2CDK4ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
WO-2010009155-A2 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 CDK2 16/4885CDK4 15/4885ALDH1A1 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.